As of July 2022, biosimilar Nyvepria (pegfilgrastim-apgf) launched at an average sales price of 16 percent higher than Neulasta's ASP, while the biosimilar drug Fulphila (pegfilgrastim-jmdb) launched at an average sales price of six percent less than Neulasta's. This statistic illustrates the wholesale acquisition cost and average sales price of Neulasta (pegfilgrastim) biosimilars in the United States.
Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Amgen. (October 31, 2022). Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022 [Graph]. In Statista. Retrieved December 30, 2024, from https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
Amgen. "Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022." Chart. October 31, 2022. Statista. Accessed December 30, 2024. https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
Amgen. (2022). Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022. Statista. Statista Inc.. Accessed: December 30, 2024. https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
Amgen. "Wholesale Acquisition Cost (Wac) and Average Sales Price (Asp) of Neulasta (Pegfilgrastim) Biosimilars in The United States as of 2022." Statista, Statista Inc., 31 Oct 2022, https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
Amgen, Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022 Statista, https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/ (last visited December 30, 2024)
Wholesale acquisition cost (WAC) and average sales price (ASP) of Neulasta (pegfilgrastim) biosimilars in the United States as of 2022 [Graph], Amgen, October 31, 2022. [Online]. Available: https://www.statista.com/statistics/1275671/wac-and-asp-of-neulasta-pegfilgrastim-biosimilars-us/
